Effect of Placental Derived Nucleoproteins on liver regeneration in DEN-induced liver fibrosis model

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Nasr S.M.; Hassan M.; Abou-Shousha T.; Elhusseny Y.; Elzallat M.

Journal: Biomedicine and Pharmacotherapy

Publisher: Elsevier Masson s.r.l.

Publication Date: September 2024

Volume / Issue: Volume 178

Article No.: 117190

ISSN: 7533322

DOI: 10.1016/j.biopha.2024.117190

Scopus: View on Scopus

PubMed: 39067160

Document Type: Article

Access: All Open Access; Gold Open Access


Authors and Affiliations

Nasr S.M., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, 12411, Egypt, School of Biotechnology, Badr University in Cairo, Badr City, Cairo, 11829, Egypt; Hassan M., Department of Immunology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Abou-Shousha T., Department of Pathology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Elhusseny Y., School of Medicine, NewGiza University, Giza, 12585, Egypt; Elzallat M., Department of Immunology, Theodor Bilharz Research Institute, Giza, 12411, Egypt


Abstract

Background: Placental Derived Nucleoproteins (PDNs) is commonly associated with the process of angiogenesis, and doesn't affect the healthy vasculature. PDNs are clinically estimated for the treatment of cancer cases and severe hepatic injuries. Thus, the pathophysiological effects of PDNs targeting liver fibrosis is a concern. Objectives: To assess the molecular, histopathological, and chemical impact of PDNs on liver regeneration in Diethylnitrosamine (DEN)-induced mice liver fibrosis. Methods: Normal untreated reference group of ten mice and two groups of induced liver cirrhosis using the recommended weekly dose of Diethylnitrosamine in total of eleven doses, initially 20 mg/kg body weight, and then 30 mg/kg in the third week, followed by 50 mg/kg for the last eight weeks, one of them combined treatment aligned with injection with total dose of extracted PDNs 25 mg/kg, in comparison to PDNs only treated group. An autopsy was performed after 22 weeks of the initial dose of DEN in each group. Molecular characterization of Alpha smooth muscle actin, TGFβ and NF-κB biomarkers for liver then liver function panel were analyzed and finally hepatopathological changes were observed using H&E stain and Sirius red stain. Results: Liver enzymes, total bilirubin and total proteins in tissue in PDNs-DEN treated models were controlled in the direction of normal group and 50 % reduction of fibrosis in comparing to DEN-treated models. The cellular arrangement of fibrosis in the DEN entire groups were differentiated with high significant impact on the survival of mice. Increased levels of the biochemical markers in liver homogenate, loss of tissue architecture, and proliferation were observed in induced groups and down regulation of alpha smooth muscle actin, TGFβ and NF-κB. Conclusion: This finding demonstrates an improvement of Liver tissue induced fibrosis using DEN combined with PDNs. This strategy is to generate an animal model with a lower occurrence of fibrosis in a short time treatment regarding liver regeneration. © 2024 The Authors


Keywords

Animal model; Diethylnitrosamine; Liver fibrosis; Liver regeneration; Placental Derived Nucleoproteins; Actins; Animals; Disease Models, Animal; Female; Liver; Liver Cirrhosis; Male; Mice; NF-kappa B; Placenta; Pregnancy; Transforming Growth Factor beta; albumin; alpha smooth muscle actin; bilirubin; bovine serum albumin; immunoglobulin enhancer binding protein; liver enzyme; nucleoprotein; actin; animal experiment; animal tissue; Article; blood sampling; cell proliferation; comparative study; controlled study; cytokine production; DNA transcription; down regulation; gene expression profiling; histopathology; liver function; liver homogenate; mouse; nonhuman; therapy effect; animal; disease model; drug effect; drug therapy; metabolism; pathology


Citation Information

Scopus Citations: 3


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region